ADAC issues restated financial numbers
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, this month issued restated financial results for the years 1996 through 1999 (see chart). At the same time, the company released financial results for the first quarter of 1999 (end-January) that
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, this month issued restated financial results for the years 1996 through 1999 (see chart). At the same time, the company released financial results for the first quarter of 1999 (end-January) that indicate that the restatement imbroglio has not slowed down the companys business prospects.
ADAC announced last year that it would restate its financial results for three years because of more stringent controls over how the company recognizes revenue. The company also adjusted some extraordinary charges taken during the three-year period. The restatements would not eliminate any sales, but rather would push them into later quarters, the company said. The announcement prompted a slide in ADACs stock and the filing of a half-dozen shareholder suits that the company is still defending (SCAN 1/13/99).
For the first quarter of fiscal 1999, ADAC posted sales of $94.3 million, an increase of 40% over the $64.7 million reported in the restated first quarter of 1998. The company recorded net income of $3.9 million, an amount that reflected the impact of $2.5 million in charges to restructure the companys international operations and $1.6 million in auditors and legal fees related to the restatement process. ADAC CEO Andrew Eckert said the company is optimistic about its prospects for 1999, and is booking orders in all its businesses at record rates.
Study Examines CT-Based AI Detection of Incidental Abdominal Aortic Aneurysms
April 29th 2025The AI software Viz AAA offered a sensitivity of 87.5 percent in detecting abdominal aortic aneurysms on contrast-enhanced CT, according to new retrospective research presented at the American Roentgen Ray Society (ARRS) conference.
